Economic Evaluation of Pharmaceuticals in Israel: Current and Future National Policy

S Shani, J Shemer

Research output: Contribution to journalArticlepeer-review


WORKSHOP OBJECTIVE: The purpose of this workshop will be to identify the economic data needed for the decision-maker in order to make his decision. The reasons for which economic evaluation has a relatively low impact on healthcare decision-making and interventions that could change this situation, will be discussed. PARTICIPANTS WHO WOULD BENEFIT: Government and healthcare industry decision-makers and other professionals involved in submitting economic evaluations to decision-makers. Israel’s Health Insurance Law states that health services included in the List of Health Services will be of reasonable quality within the framework of the funding sources available. The inherent scarcity of resources for health services in Israel, like in other western countries, together with the rapid development of new and expensive health technologies makes updating the list of health services a complicated task. The Pharmaceutical Administration set up a mechanism for updating the National List of Reimbursed Pharmaceuticals (NLRD) which is a part of the obligatory List of Health Services each citizen is entitled to get. The Pharmaceutical Administration took a systematic approach of health technology assessment: Adhoc teams were established for evaluating clinical safety, efficacy and effectiveness, conducting needs assessment and economic analysis. An initial filtering process was taken in order to screen only beneficial and affordable technologies. This procedure leads to a list of new pharmaceuticals suggested for inclusion in the NLRD. In this workshop, we will present the current policy concerning economic evaluation in Israel and the planned policy, covering issues such as submission of a dossier which includes important parameters like drug prices and their justification, affordability of the new drug and a specified economic analysis.
Original languageEnglish
Pages (from-to)232
JournalValue in Health
Issue number3
StatePublished - 1999
Externally publishedYes


Dive into the research topics of 'Economic Evaluation of Pharmaceuticals in Israel: Current and Future National Policy'. Together they form a unique fingerprint.

Cite this